Xeomin: The “Naked” Wrinkle Relaxer and When It Makes Sense for You

What Is Xeomin?

Xeomin (also called incobotulinumtoxinA) is an FDA-approved injectable neurotoxin used to reduce dynamic facial wrinkles — the lines that form when you make facial expressions. It was approved by the FDA in March 2011.

Like Botox and Dysport, Xeomin is made from botulinum toxin type A, a purified protein that temporarily relaxes facial muscles. What makes Xeomin different is its formulation: it is sometimes called the “naked” neurotoxin because it contains only the active toxin molecule, without the complexing proteins (accessory proteins) that surround the toxin in Botox and Dysport.

• Botox molecule complex: 900 kDa (kilodaltons, a measure of protein size)
• Dysport molecule complex: 300 kDa
• Xeomin molecule: 150 kDa (the active toxin alone, no extras)

The theory is that these extra proteins in Botox may trigger your immune system to produce antibodies (proteins that can neutralize a substance), which over time can reduce how well the treatment works. Xeomin’s protein-free formulation may reduce this risk, though the real-world difference is modest.

How It Works

Xeomin works the same way as other botulinum toxin products. When injected into a facial muscle, it blocks the signal between the nerve and the muscle by preventing the release of a chemical messenger called acetylcholine. Without this signal, the muscle relaxes, and the overlying skin smooths out.

The specific wrinkles that respond best to Xeomin are dynamic wrinkles — lines caused by repeated muscle movement, such as:

• Glabellar lines (the “11s” or frown lines between your eyebrows)
• Crow’s feet (lines at the outer corners of your eyes)
• Forehead lines

Static wrinkles — lines present even when your face is at rest — typically respond better to dermal fillers than to neurotoxins like Xeomin.

What to Expect During Treatment

• Consultation: Your provider will assess your facial muscles, wrinkle patterns, and treatment history, including whether you have had prior neurotoxin treatments and how well they worked.
• Injections: A small needle delivers precise amounts of Xeomin into targeted muscles. The procedure typically takes 10–20 minutes.
• Dosing: FDA-approved doses are 20 units for glabellar lines, 12 units per side for crow’s feet, and 10–20 units for forehead lines. Xeomin units are approximately equivalent 1-to-1 with Botox units (unlike Dysport, which uses a different unit scale).
• Discomfort: Mild and brief. A topical numbing cream can be applied beforehand if desired.
• No downtime: You can return to normal activities immediately, though you should avoid rubbing the treated areas and strenuous exercise for the rest of the day.

Results and Recovery

• Onset: You will start to notice muscle relaxation at 5–7 days. Full effect is typically visible by day 10–14.
• Duration: Results last approximately 12–16 weeks (3–4 months) on average, similar to Botox. Some patients notice Xeomin fading slightly faster than Botox at the same dose — approximately 15% of patients report this experience.
• Repeat treatments: Most patients schedule treatments 3–4 times per year. Repeated use does not cause tolerance (the product does not stop working simply because you have used it repeatedly).
• Clinical results: In FDA clinical trials, 68% of patients showed marked or moderate improvement in glabellar lines at 30 days. In a crow’s feet trial, 70% showed improvement at day 30 with 12 units per side.

Benefits and Risks

Benefits of Xeomin:

• Effective wrinkle relaxation comparable to Botox
• Protein-free formulation may reduce long-term risk of antibody development
• Good option for patients who have developed resistance to Botox or Dysport
• Dosing is straightforward: 1 Xeomin unit approximately equals 1 Botox unit
• Similar cost to Botox ($8–12 per unit)

Possible side effects and risks:

• Headache (1–7% of patients)
• Temporary bruising at injection sites (approximately 10%)
• Mild swelling (5–10%)
• Eyelid drooping, called ptosis (0.5–1%) — temporary and resolves as the product wears off
• Asymmetry requiring a touch-up (10–20%)
• Antibody formation over time (estimated 0.5–1% annually with Xeomin vs. 1–2% with Botox)

Xeomin is contraindicated (should not be used) during pregnancy, breastfeeding, in patients with certain neuromuscular diseases, and in those taking aminoglycoside antibiotics. Severe allergic reactions are extremely rare.

Who Is a Good Candidate?

Xeomin is worth considering if you:

• Have tried Botox or Dysport and found that it stopped working despite proper dosing and technique (documented immunoresistance)
• Prefer a formulation without complexing proteins for theoretical long-term benefit
• Are a first-time neurotoxin patient who would like an alternative to Botox
• Want balanced diffusion — Xeomin spreads about 0.7–1 cm from the injection site, which is useful for both precision (around the eyes) and coverage (forehead)

For most first-time patients, Botox remains the most common recommendation because of its 20+ year track record of safety and efficacy data. Xeomin fills an important role as a second-line treatment for immunoresistant patients, and as a primary option for patients with a specific preference for the protein-free formulation.

When to See a Dermatologist

Seek care from a board-certified dermatologist with experience in multiple neurotoxin formulations, especially if:

• Your Botox or Dysport results have been declining despite consistent dosing
• You experienced asymmetry, over-correction, or under-correction with a previous neurotoxin
• You are interested in switching products and want guidance on proper dosing conversion

Contact your provider or seek emergency care immediately if you experience vision changes, difficulty swallowing or breathing, or significant eyelid drooping that persists beyond 2 weeks.

Frequently Asked Questions

Q: If Botox stopped working for me, will Xeomin work?
A: Approximately 40–50% of patients who no longer respond to Botox regain a good response when switched to Xeomin or Dysport. The switch is worth trying after multiple failed Botox treatments (3 or more sessions with proper dosing). However, if poor results from Botox were due to incorrect dosing or injection technique rather than true antibody resistance, switching products alone will not help — the technique issue needs to be addressed with a more experienced injector.

Q: Is the “naked” formulation actually better than Botox?
A: For most patients, results are equivalent. The theoretical advantage of Xeomin’s protein-free formula is a modest reduction in the chance of developing antibodies over time — roughly 0.5–1% per year versus 1–2% with Botox. This difference is real but small, and does not translate to meaningfully better results for the average patient. Xeomin’s primary advantage shows up in patients who have already developed antibody resistance to other products.

Q: How does the cost of Xeomin compare to Botox?
A: Costs are similar. Xeomin typically runs $8–12 per unit, compared to $10–15 per unit for Botox. Since Xeomin and Botox use the same unit scale (1:1), total treatment costs are roughly equivalent. A standard 100-unit treatment would cost approximately $800–1,200 with Xeomin versus $1,000–1,500 with Botox. Cosmetic neurotoxin treatments are rarely covered by insurance.

Q: How do I know if I have developed antibodies to Botox?
A: True antibody resistance means Botox has stopped producing any effect, even with adequate dosing from an experienced injector. One disappointing result does not confirm resistance — that could be a dosing or technique issue. Your provider will suspect true resistance after 3 or more sessions at proper doses that produce no meaningful muscle relaxation. A trial with Xeomin is often used as a diagnostic test: if Xeomin works when Botox did not, it supports the conclusion that antibodies to the Botox protein complex were the cause.